Floatz logo

Osimertinib

Solid Tumours

AstraZenecaSmall moleculePhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Solid Tumours cohort.

Asset / SponsorPhaseRating
bh009
Zhuhai Beihai Biotech Co., Ltd
Phase 3B
gw786034
Novartis Pharmaceuticals
Phase 2B
gsk1120212
GlaxoSmithKline
Phase 2B
Docetaxel
Zhuhai Beihai Biotech Co., Ltd
Phase 3B
Dabrafenib
GlaxoSmithKline
Phase 2B

View all 50 →

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →